Bloom Burton

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

AceAge is a healthcare technology company, creating intuitive products to ease the aging process and improve health outcomes. AceAge is the company behind the next innovation in healthcare technology. Its upcoming product is a home health appliance designed to help people take their medication properly. Karie is a personal health companion that organizes, schedules, and dispenses pills with easy one-button control. The CEO of AceAge, Spencer Waugh, created Karie to increase the health and safety of medical patients, and as a way to minimize the negative consequences of missed medications or general failure to adhere to medication directions. The success of medicine is dependent on the patient’s compliance with the medical directions that accompany it, making it an integral part of healthcare. The total direct and indirect costs of nonadherence in the US annually is $290 billion. By making daily medicine routines completely automated, Karie removes the chance of human error. Karie uses common multi-dose pouch packaging that can be pre-set by pharmacists. Doses are scheduled, delivered and monitored for the user. Karie is easy to use, enables greater patient autonomy and ensures better healthcare through a highly coordinated program.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Antibe Therapeutics develops novel anti-inflammatory drugs that are improved versions of existing drugs. They focus on diseases characterized by inflammation, pain, and/or vascular dysfunction. Their drug design approach is to create new drugs by improving existing, proven drugs. The company's technology platform enables us to chemically link an existing drug to a hydrogen sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so-called gaseous mediators. Gaseous mediators are naturally occurring substances found in the human body. Acting as neuromodulators, immunomodulators, and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential. Antibe’s R&D is guided by a leading team of pharmaceutical researchers and advisors. The team includes a Nobel Prize winner, highly successful entrepreneurs, and senior scientists affiliated with major research institutions worldwide.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

HLS Therapeutics Inc is a specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceutical products in North America. The company is dedicated to managing the life cycles of these products after exclusivity, ensuring the availability of essential treatments for patients and caregivers. HLS's portfolio includes notable products such as Clozaril, Vascepa, and CSAN Pronto. The majority of the company's revenue is generated through product sales, supplemented by royalties. HLS operates primarily in Canada and the United States, as well as in other international markets.

Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and providing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used for the treatment of hypertension. Noden Pharma aims to enhance the lives of patients by offering effective medical solutions in international markets.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

Profound Medical Corp. is a medical technology company that specializes in developing magnetic resonance-guided ablation procedures for treating prostate disease, uterine fibroids, and palliative pain management. The company’s primary product, the TULSA-PRO system, integrates real-time MRI guidance with ultrasound technology to provide precise, non-invasive treatment options for various conditions. Additionally, Profound Medical offers the Sonalleve platform, which targets uterine fibroids and bone metastases, enhancing the range of therapeutic solutions available to clinicians. The company collaborates with GE Healthcare to improve access to its TULSA-PRO system in medical facilities. Headquartered in Mississauga, Canada, Profound Medical is dedicated to advancing the standard of care by enabling safe and effective treatment alternatives for patients, allowing them to return to their daily lives more quickly.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Medicago Inc. is a biotechnology company based in Quebec City, Canada, specializing in the research, development, production, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and Virus-Like Particle (VLP) technologies to create innovative vaccines and therapeutics aimed at infectious diseases and public health challenges. Medicago's product pipeline includes a candidate for the H5N1 pandemic influenza VLP vaccine, which has successfully completed a Phase I clinical trial, as well as an H1N1 VLP vaccine and seasonal influenza vaccines. The company has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the manufacturing of its vaccines, and with Philip Morris International to develop a therapeutic protein. Medicago was incorporated in 1997 and continues to focus on addressing emerging health threats through its advanced vaccine technologies.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, focused on developing innovative therapies for cancer treatment. Its primary product, pelareorep, is an immuno-oncology agent derived from reovirus, designed to enhance the immune system's ability to target and eliminate tumors, particularly those with an activated Ras pathway. The company has established collaboration agreements with Merck KGaA and Pfizer to explore the use of pelareorep in combination with other treatments for specific types of cancer, including hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. In addition to pelareorep, Oncolytics Biotech is advancing other projects in its pipeline aimed at various cancers, including breast and gastrointestinal cancers. Founded in 1998, Oncolytics Biotech continues to seek novel approaches to address unmet medical needs in oncology.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration, particularly in severe disorders. The company's primary focus is on creating an oral therapeutic drug for Duchenne muscular dystrophy, targeting the dysregulation that is recognized as a fundamental cause of the disease's progressive characteristics. Through its research and development efforts, Satellos aims to address significant unmet medical needs within the field of muscle-related conditions.